Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid

Table 3

Medical history, date of diagnosis, and treatment course of neurological disorders of Adult T-cell Leukemia/Lymphoma (ATL) patients, diagnosed between 1st January 1983 and 31st March 2013, presenting with a survival superior to 10 years (long survival) in Martinique.

Patient	Age (years)	Gende	Medical history (time period)	Neurological disorders (time period)	Start of valproic acid (VA) treatment	ATL clinical subtype (diagnosis date)	ATL treatment	Survival period at 31st March 2013 (months)
1	46	F	Neo-uterus (1983)	Epilepsy (1975)	1975	Chronic (1995)	IF, Hivid	216
2	40	F	Chickenpox	Depressive syndrome (2004)	2004	Chronic (2001)	IF, combivir-VP1	142
3	46	F		Chronic psychosis with an epileptical background (1996)	1999	Chronic (1996)	—	205
4	50	M	Inguinal hernia, alcoholism	Disabling neuropathy (2004)	2004	Lymphoma (2001)	CHO, IF-VP1, Hivid, combivir	128
5	34	M	Posttransfusion hepatitis C (2000)/IF	Craniostenosis/surgery (1985)	1985	Lymphoma (2000)	CHO, VP1, Hivid	160
6	62	F	Hookworm disease	No	—	Lymphoma (2000)	—	129 (deceased)
7	16	F		No	—	Chronic (2000)	VP1, combivir, IF, rituximab	150
8	36	M	Perinatal exchange transfusion, malaria, smoking, alcoholism	No	—	Lymphoma (2002)	VP1, COP, COPAD, MTX, AZT, IF, combivir	132
9	68	M	Erythroderma (1993),; strongyloidiasis (1994),; alcoholism	No	—	Chronic (2000)	CHO, VP1	132 (deceased)
10	45	F	Hypertension, kidney failure (1988),   kidney transplant on nephroangiosclerosis (1990), Ig kappa peak	No	—	Lymphoma (1995)	CHO, MT, caryolysine, Epivir, photochemotherapy, radiotherapy	130 (deceased)

M: male, F: female, IFN: interferon, IgG: immunoglobulin G, CHOP: cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone, COPP: cyclophosphamide, oncovin, procarbazine, and prednisolone, VP16: vepezide 16, COPADM: cyclophosphamide, vincristine, prednisolone, doxorubicin, and methotrexate, MTX: methotrexate, AZT: azidothymidine, Hivid/combivir: nucleoside analog reverse transcriptase inhibitor, rituximab: monoclonal antibody anti-CD20, caryolysine: chlormethine chlorhydrate, and Epivir: doxorubicine chlorhydrate.